Liraglutide
Liraglutide is listed as Victoza, a once-daily auto-injector for Type 2 Diabetes Mellitus. As a GLP-1 receptor agonist, it increases insulin release when blood sugar rises.
Key points
- Liraglutide carries a boxed warning for thyroid C-cell tumours observed in rodent studies. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Unlike native GLP-1, liraglutide resists breakdown by peptidases, which is what makes once-daily dosing possible rather than multiple injections.
What the boxed warning means for a reader
The rodent finding is dose-dependent and duration-dependent, but whether liraglutide causes medullary thyroid carcinoma in humans remains unknown; the label states plainly that human relevance has not been determined. Because of that uncertainty, the contraindication does the protective work rather than surveillance: routine serum calcitonin testing and thyroid ultrasound are of uncertain value for early detection in people taking this medicine. Symptoms worth reporting include a mass in the neck, difficulty swallowing, difficulty breathing, or persistent hoarseness. Within Diabetes Management, Victoza sits at 6 mg in a single auto-injector presentation, and the thyroid warning is the label detail that most directly shapes who can and cannot use it.